Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.09 USD | +0.33% | -10.91% | -19.02% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.02% | 1.3B | C- | ||
+72.65% | 12.28B | B- | ||
-19.41% | 7.81B | C+ | ||
+14.98% | 7.19B | C- | ||
-5.13% | 5.23B | B | ||
+5.78% | 4.94B | D+ | ||
+17.02% | 4.24B | - | ||
-25.36% | 3.97B | B- | ||
-40.56% | 2.24B | C | ||
-3.47% | 1.92B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVCR Stock
- Ratings NovoCure Limited